Shire PLC (LON:SHP) Rating Reaffirmed
Exane BNP Paribas now has a GBX 5700.00 target price on the 26.74 billion GBP market cap company or 24.33% upside potential. In an analyst note sent to investors on Tuesday, 8 December, Shire PLC (LON:SHP) shares have had their “Neutral” Rating reaffirmed by equity research analysts at Exane BNP Paribas.
From a total of 10 analysts covering Shire PLC (LON:SHP) stock, 11 rate it a ”Buy”, 0 a “Sell”, and 6 a ”Hold”. This means that 65% of the ratings are positive. The highest target price is GBX 96.71 while the lowest target price is GBX 81.77. The mean of all analyst targets is GBX 89.63 with a 19.35% above today’s (GBX 4514) stock price. Shire PLC was the topic of 82 analyst reports since July 24, 2015 according to the firm StockzIntelligence Inc. Bernstein maintained shares on December 7 with “Outperform” rating. Credit Suisse maintained shares with “Neutral” rating and GBX 5400 target share price in a report from a November 4. J.P. Morgan maintained SHP stock in a recent report from December 4 with “Overweight” rating. Barclays Capital maintained the rating on November 3. Barclays Capital has a “Overweight” rating and a GBX 5700 price target on shares. Finally, Berenberg maintained the stock with “Buy” rating in a report issued on a November 16.
Approximately 13,015 shares of stock traded hands. Shire PLC (LON:SHP) has declined 14.11% since May 11, 2015 and is downtrending. It has underperformed by 13.52% the S&P500.
Shire plc is a biopharmaceutical company. The company has a market cap of 26.74 billion GBP. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. It has 13.28 P/E ratio. The Firm commercializes its products in the areas of Neuroscience, Gastrointestinal , Rare Diseases and Other therapeutic areas.